TG Therapeutics (TGTX) revenue

Revenue · fiscal 2025
$616.29M

TG Therapeutics (TGTX) reported revenue of $616.29M in fiscal 2025 (the year ended December 31, 2025). That is 87.3% higher than the $329.00M of fiscal 2024. Figures as of 18 Nov 2026, 11:52 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$616.29M
Change on fiscal 2024
+87.3%
Growth, 5 years
+426.7% a year
Highest on record
$616.29Mfiscal 2025
Lowest on record
$152.00Kfiscal 2016
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

TG Therapeutics revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 426.7% a year. Across the 10 fiscal years on record (2016–2025), the highest was $616.29M in fiscal 2025 and the lowest $152.00K in fiscal 2016.

History · 10 fiscal years

Revenue by fiscal year

TG Therapeutics revenue, year by year

TG Therapeutics (TGTX) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$616.29M 87.3% up
2024$329.00M 40.8% up
2023$233.66M 8,290.0% up
2022$2.79M 58.4% down
2021$6.69M 4,300.7% up
2020$152.00K 0.0%
2019$152.00K 0.0%
2018$152.00K 0.0%
2017$152.00K 0.0%
2016$152.00K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of TG Therapeutics and comparable companies
CompanyRevenueFiscal year
Madrigal Pharmaceuticals MDGL$958.40M2025
Henry Schein HSIC$13.18B2025
Oscar Health OSCR$11.70B2025
TG Therapeutics TGTX$616.29M2025
Praxis Precision Medicines PRAX$8.55M2024
Twist Bioscience TWST$459.43M2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TGTX

TG Therapeutics, figure by figure

TG Therapeutics (TGTX) overview: price, valuation and scorecardAll health care companies by market value

TG Therapeutics revenue: questions and answers

What is TG Therapeutics's revenue?

TG Therapeutics (TGTX) reported revenue of $616.29M in fiscal 2025 (the year ended December 31, 2025). That is 87.3% higher than the $329.00M of fiscal 2024.

What is the growth rate of TG Therapeutics's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 426.7% a year.

What are the highest and lowest revenue figures on record for TG Therapeutics?

Across the 10 fiscal years on record (2016–2025), the highest was $616.29M in fiscal 2025 and the lowest $152.00K in fiscal 2016.

How is TG Therapeutics's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For TG Therapeutics it is on record here for 10 fiscal years, 2016 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “TG Therapeutics (TGTX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/TGTX/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.